Celentyx Ltd News Release  
8th July 2009

Celentyx announces collaboration with natural products drug company Hypha Discovery Ltd to support its research programme on novel oncology drugs.

BIRMINGHAM, UK – 8th July, 2009 - Celentyx Ltd announced today that Hypha Discovery Ltd has signed an agreement to access Celentyx’s Immuno-Profiling™ platform technology. The collaboration will bring together Hypha’s extensive expertise in natural products lead discovery and Celentyx’s high resolution human immune capabilities.

Celentyx’s Immuno-Profiling™ platform allows rapid analysis of drug action on human immune cells. Drawing on the world-leading expertise of Celentyx personnel, which along with Celentyx’s close association with the MRC Centre for Immune Regulation, enables the human immune system to be investigated at the highest levels of resolution.

Hypha has an early-stage pipeline of novel natural products that have significant activity against tumour cell lines - led by the fully synthetic anti-cancer chemical series HD148 - inspired by compounds produced in the fermentation of a specific tropical mushroom. Celentyx will apply their Immuno-Profiling™ technology to provide specific mechanistic information on Hypha’s compounds to further direct the pre-clinical development programmes.

"We are delighted to have the opportunity to work with an innovative company such as Hypha Discovery," said Professor Nicholas Barnes, CEO of Celentyx. "We look forward to supporting Hypha to take their project forward using our Immuno-Profiling™ platform technology ".

Dr Jonathan Steele, Chief Scientific Officer of Hypha Discovery Ltd, said: “Access to Celentyx’s expertise is key to help progress our novel oncology drug programme. We are confident their input will accelerate growth of our intellectual property portfolio”.

- ENDS -

Further information and high resolution images:
Dr Catherine Brady, Celentyx Ltd
Tel: +44 (0)121 414 8199 / Mobile: +44 (0)7725 963391
Email: catherine.brady@celentyx.com

www.celentyx.com
NOTES TO EDITORS

About Celentyx Ltd

Celentyx Ltd is a human immune system focused R&D and service company. Celentyx’s unique Immuno-Profiling™ platform allows rapid analysis of drug action on human immune cells. Drawing on the World-leading expertise of Celentyx personnel, which along with our close association with the MRC Centre for Immune Regulation, enables the human immune system to be investigated at the highest levels of resolution.

Celentyx's Immuno-Profiling™ services enable partners to elucidate the mechanism of action of an immunomodulatory drug – at both the cellular and molecular level, facilitate lead candidate prioritisation or identify potentially negative impact of a drug on the human immune system prior to first administration to man.

About Hypha Discovery Ltd.

• Hypha is a privately held pharmaceutical discovery company uniquely placed to discover novel drug-leads from a collection of 2,500 highly diverse mushroom fungi (the basidiomycetes), much of it from tropical rainforest.

• The company is expert in discovering bioactive compounds from fermentations of the collection, with a high proportion of novelty (about 50%) which is unusual for modern natural products discovery.

• Hypha has internal research programmes targeted for antibiotic and anticancer compound discovery. Currently five separate anti-cancer projects are being progressed, led by the HD148 programme – a fully synthetic series of compounds.

• Hypha is seeking collaborations with companies with a need for novel active compounds for pharmaceutical development, as well as those interested in novel enzymes for biofuel applications and other macromolecules.

• Hypha also provides contract services to pharmaceutical and biotechnology companies, for compound purification and identification (e.g. manufacturing impurities, natural products from various sources), and biological assays (anticancer, antibacterial and antifungal).

For more information, contact Liam Evans, Hypha Discovery Ltd, Russell Building No.1, Brunel Science Park, Kingston Lane, Uxbridge, UB8 3PQ, UK

liam.evans@hyphadiscovery.co.uk
Tel +44 (0)1895 814595

www.hyphadiscovery.co.uk